APA (7th ed.) Citation

T, C., CH, L., A, W., A, P., BW, C., MCB, G., . . . B, S. (2023). Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: The phase 2 platform NEOSTAR trial. Nature medicine, 29(3), 593. https://doi.org/10.1038/s41591-022-02189-0

Chicago Style (17th ed.) Citation

T, Cascone, et al. "Neoadjuvant Chemotherapy Plus Nivolumab with or Without Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Platform NEOSTAR Trial." Nature Medicine 29, no. 3 (2023): 593. https://doi.org/10.1038/s41591-022-02189-0.

MLA (9th ed.) Citation

T, Cascone, et al. "Neoadjuvant Chemotherapy Plus Nivolumab with or Without Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Platform NEOSTAR Trial." Nature Medicine, vol. 29, no. 3, 2023, p. 593, https://doi.org/10.1038/s41591-022-02189-0.